ARTICLE | Distillery Therapeutics
Cancer
April 10, 2018 10:50 PM UTC
Mouse studies suggest inhibiting KDM5A could help treat RB1-deficient retinoblastoma. In an RB1-haploinsufficient mouse model of retinoblastoma, systemic knockout of KDM5A decreased tumor growth and i...
BCIQ Company Profiles